| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial HA Burris, MJ Moore, J Andersen, MR Green, ML Rothenberg, ... Journal of clinical oncology 15 (6), 2403-2413, 1997 | 7216 | 1997 |
| Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine DD Von Hoff, T Ervin, FP Arena, EG Chiorean, J Infante, M Moore, T Seay, ... New England journal of medicine 369 (18), 1691-1703, 2013 | 5956 | 2013 |
| Risk factors for doxorubicin-lnduced congestive heart failure DD Von Hoff, MW Layard, P Basa, HL DAVIS Jr, AL Von Hoff, ... Annals of internal medicine 91 (5), 710-717, 1979 | 2970 | 1979 |
| Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma PP Provenzano, C Cuevas, AE Chang, VK Goel, DD Von Hoff, ... Cancer cell 21 (3), 418-429, 2012 | 1942 | 2012 |
| Hypersensitivity reactions from taxol. RB Weiss, RC Donehower, PH Wiernik, T Ohnuma, RJ Gralla, DL Trump, ... Journal of clinical oncology 8 (7), 1263-1268, 1990 | 1503 | 1990 |
| Inhibition of the hedgehog pathway in advanced basal-cell carcinoma DD Von Hoff, PM LoRusso, CM Rudin, JC Reddy, RL Yauch, R Tibes, ... New England Journal of Medicine 361 (12), 1164-1172, 2009 | 1302 | 2009 |
| Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies M Hidalgo, LL Siu, J Nemunaitis, J Rizzo, LA Hammond, C Takimoto, ... Journal of clinical oncology 19 (13), 3267-3279, 2001 | 1234 | 2001 |
| ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents C Heise, A Sampson-Johannes, A Williams, F Mccormick, DD Von Hoff, ... Nature medicine 3 (6), 639-645, 1997 | 1188 | 1997 |
| Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449 CM Rudin, CL Hann, J Laterra, RL Yauch, CA Callahan, L Fu, T Holcomb, ... New England Journal of Medicine 361 (12), 1173-1178, 2009 | 1165 | 2009 |
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial DD Von Hoff, RK Ramanathan, MJ Borad, DA Laheru, LS Smith, TE Wood, ... Journal of Clinical Oncology 29 (34), 4548, 2011 | 1163 | 2011 |
| Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ... Science translational medicine 4 (128), 128ra39-128ra39, 2012 | 1128 | 2012 |
| Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. KE Noonan, C Beck, TA Holzmayer, JE Chin, JS Wunder, IL Andrulis, ... Proceedings of the National Academy of Sciences 87 (18), 7160-7164, 1990 | 1061 | 1990 |
| Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open … A Wang-Gillam, CP Li, G Bodoky, A Dean, YS Shan, G Jameson, ... The Lancet 387 (10018), 545-557, 2016 | 1039 | 2016 |
| Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer E Van Cutsem, H Van De Velde, P Karasek, H Oettle, WL Vervenne, ... Journal of clinical oncology 22 (8), 1430-1438, 2004 | 966 | 2004 |
| A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer ML Rothenberg, MJ Moore, MC Cripps, JS Andersen, RK Portenoy, ... Annals of Oncology 7 (4), 347-353, 1996 | 738 | 1996 |
| Toxic effects of cis-dichlorodiammineplatinum (II) in man. DD Von Hoff, R Schilsky, CM Reichert, RL Reddick, M Rozencweig, ... Cancer treatment reports 63 (9-10), 1527-1531, 1979 | 725 | 1979 |
| Tumor-stroma interactions in pancreatic ductal adenocarcinoma D Mahadevan, DD Von Hoff Molecular cancer therapeutics 6 (4), 1186-1197, 2007 | 720 | 2007 |
| Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development EK Rowinsky, JJ Windle, DD Von Hoff Journal of Clinical Oncology 17 (11), 3631-3652, 1999 | 674 | 1999 |
| American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants ML Hensley, KL Hagerty, T Kewalramani, DM Green, NJ Meropol, ... Journal of clinical oncology 27 (1), 127-145, 2009 | 647 | 2009 |
| nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial D Goldstein, RH El-Maraghi, P Hammel, V Heinemann, V Kunzmann, ... JNCI: Journal of the National Cancer Institute 107 (2), 2015 | 632 | 2015 |
